Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Oncology
Purdue Pharma L.P. Announces a Global Strategic Alliance With Infinity Pharmaceuticals to Advance Discovery and Development Programs in Oncology and Neuropathic Pain
December 2nd, 2008
Purdue Pharma L.P. and Mundipharma International Corporation Limited, announced that they have entered into a global strategic alliance with Infinity Pharmaceuticals, Inc. to advance the research, development, and commercialization of Infinity's discovery and early clinical programs in the areas of oncology and neuropathic pain. The alliance will focus on supporting Infinity's pipeline of novel, small molecule oncology drug candidates, including IPI-926, a potent inhibitor of the Hedgehog pathway, which is being evaluated in a Phase 1 clinical study in patients with advanced solid tumors. IPI-926 has demonstrated significant anti-tumor activity in a number of...
Source: Cancer Weekly (2008-12-02)
|
